Unraveling the Gender Gap: Why Women Face a Higher Risk of Alzheimer’s Disease Alzheimer’s disease impacts women at nearly double the rate of men, prompting scientists to explore causes that go far beyond longer life expectancy. While a woman’s lifespan was once considered the m... Alzheimer's brain health genetics hormones hormone therapy menopause neurology women's health
Repurposed Cancer Drugs Show Promise Against Alzheimer’s Brain Damage Could the answer to reversing Alzheimer’s brain damage already exist on pharmacy shelves? Recent research points to a surprising possibility: some cancer drugs may help fight the devastating effects o... Alzheimer's brain health cancer drugs clinical trials drug repurposing gene expression irinotecan letrozole
Video Games Could Transform Early Detection of Alzheimer’s Disease Envision a world where playing a video game could reveal Alzheimer’s disease years before symptoms appear. Researchers at Rutgers-Newark are pioneering this possibility, developing computerized games ... Alzheimer's blood tests brain health clinical trials cognitive testing early detection inclusive research video games
Unlocking Alzheimer’s Mysteries: How PHGDH Changes the Game Alzheimer’s disease remains one of the most challenging neurodegenerative conditions, particularly in its late-onset form (LOAD), which strikes millions without clear genetic risk factors. Recent rese... Alzheimer's amyloid-beta biomarkers neurodegeneration PHGDH therapeutics transcriptional regulation
MIT Researchers Chart New Paths for Alzheimer’s Drug Targets Beyond Amyloid Alzheimer’s disease has challenged the scientific community for decades, especially as treatments focused on amyloid plaques have not delivered the hoped-for results. In a promising shift, researchers... Alzheimer's computational biology DNA repair drug discovery genetics MIT neurodegeneration RNA modification
FDA Clears First Blood-Based Biomarker Test for Alzheimer's: What It Means for Patients and Providers Diagnosing Alzheimer’s disease could be as simple as a routine blood draw thanks to the FDA’s recent clearance of the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio. This innova... Alzheimer's biomarkers diagnostics FDA clearance Fujirebio neurodegenerative diseases plasma test
How Sugars on Cell Surfaces Could Unlock New Paths to Brain Resilience What if a crucial piece in the puzzle of brain aging has been hiding in plain sight, overlooked sugars on the surfaces of our brain cells. While past research zeroed in on proteins and DNA, emerging s... Alzheimer's blood-brain barrier brain aging cell surface sugars cognitive decline drug delivery glycocalyx neurodegeneration
New Genetic Pathways Offer Hope for Alzheimer’s Drug Development Alzheimer’s disease is a condition that affects millions globally and has traditionally been linked to amyloid plaques in the brain. Most drug development efforts have targeted these plaques but real-... Alzheimer's computational biology DNA repair drug discovery genetics neurodegeneration RNA modification
AI Revolutionizes How Scientists Map Protein Locations in Human Cells What if researchers could diagnose diseases or develop breakthrough drugs in a fraction of the time it takes today? Thanks to a cutting-edge artificial intelligence model from MIT, Harvard, and the Br... Alzheimer's artificial intelligence biomedical research cell biology diagnostics drug discovery machine learning protein localization
Shedding New Light on Neural Connections: How LICONN is Democratizing Brain Mapping Imagine unlocking the brain’s secrets with equipment found in a typical biology lab. Recent advances have made this possible by using light microscopy —instead of expensive electron microscopes—to map... Alzheimer's brain mapping connectomics light microscopy machine learning molecular imaging neuroscience synapses tissue expansion
Unraveling a New Culprit in Alzheimer's Disease: PHGDH Transcriptional Regulation Alzheimer's disease (AD) is a devastating neurodegenerative condition, and while genetic factors like mutations in APP, PSEN, or MAPT and the APOE4 allele are known risk factors, they don't fully expl... Alzheimer's BioChemistry NIH Funded